HomeNew producsSpecialsMy accountFAQContact Us
Search
 

Use keywords to find the product you are looking for.

 
Categories
PGD2 Inhibitors
Chromoglycate / Indomethacin A+B
D-Cloprostenol
PGD2 Inhibitor Data
Ramatroban
SARMs
Ostarine 25mg / ml, 60ml
SARMs S4 25mg / ml, 60ml
SERMs
Clomiphene 3000mg, 60ml
Raloxifene 60mg /ml, 60ml
Tamoxifen (True Twenty) 1200mg, 60ml
Toremifene Citrate 1800mg, 30ml
Toremifene Citrate 3600mg, 60ml
b2 ADRENERGENIC AGONISTS
Albuterol 6mg/ml, 60ml
Clenbuterol 200mcg/ml, 30ml
Clenbuterol 200mcg/ml, 60ml
THYROID RELATED
T3 100mcg / ml, 60ml
T4 400mcg / ml, 60ml
AROMATASE INHIBITORS
Anastrozole 30mg, 30ml
Anastrozole 60mg, 60ml
Exemestane 300mg, 30ml
Exemestane 600mg, 60ml
Letrozole 150mg, 60ml
Letrozole 75mg / 30ml
IGF-1 PEPTIDES
IGF-1 DES 1 3, 1200mcg
IGF-1 Lr3 (10 vials)
IGF-1 Lr3 (3 Vials)
IGF-1 Lr3, 1200mcg
IGF-1 RH, 1200mcg
IGF-2 Lr3 1200mcg
MGF (IGF-1Ec) 2000mcg
IGF KITS
IGF-1 DES 1 3 KIT Receptor 1200mcg
IGF-1 Lr3 KIT Receptor 1200mcg
IGF-2 Lr3 Kit Receptor 1200mcg
MELANOTROPIN PEPTIDES
Melanotan II (10 vials) 100mg
Melanotan II 10mg
Melanotan II 30mg (3 Vials)
PT-141 (Bremalanotide) 10mg
SECRETOGOGUE PEPTIDES
CJC 1295 DAC, 2000mcg
CJC 1295 DAC, 2000mcg (3 vials)
CJC-1293 (GRF [1 29]) (3 vials)
CJC-1293 (GRF [1-29]) 2000mcg
GHRP-2 (4 Vials)
GHRP-2 (receptor) 5mg
GHRP-6 (receptor), 5mg
GHRP-6, (4 vials)
GnRH, 2000mcg
Hexarelin, 2000mcg
Ipamorelin, 2000mcg
Tesamorelin, 5 vial kit, 10mg
PEPTIDES
Ghrelex (D-Lys≥ GHRP-6)
Oxytocin, 1200iu
Phospho DSIP 1000mcg
Thymosin Beta 4, 8mg (4 vial pack)
MORE RESEARCH CHEM'S
AICAR 100mg
Dapoxetine HCL 30mg/ml, 30ml
GW1516, 150mg
Ketotifen Fumarate 120mg 60ml
Rimonabant 1200mg, 60ml
Yohimbine HCL, 10mg/ml, 30ml
SELECTIVE ANTI-ANDROGENS
Cortexolone 17-Alpha Propionate
Dutasteride 30mg, 60ml
Finasteride 150mg, 30ml
PDE5 INHIBITORS
Avanafil 50mg / ml, 60ml (Presale)
Sildenafil Citrate 750mg, 30ml
Tadalafil 30mg/ml, 30ml
Tadalafil 30mg/ml, 60ml
Vardenafil 300mg, 30ml
NOOTROPICS
Dihydroergotoxine (Ergotox)
Meclofenoxate, 60g
Pramiracetam 30g
Selegiline 300mg, 30ml
PROLACTIN ANTAGONISTS
Cabergoline 15mg, 30ml
Pramipexole Hydrochloride 60mg, 60ml
A.G.E. INHIBITORS / BREAKERS
ALT-711 (thiazolium chloride), 15g
Aminoguanidine HCL 4.5g, 60ml
TELOMERASE ACTIVATORS
Astragaloside IV 20mg / ml, 60ml
Cycloastragenol 5mg / ml, 60ml
HEPATOXICITY INHIBITORS
Silibinin 100mg/ml, 60ml
Ursodeoxycholic Acid, 30g
COMBINATION SPECIALS
AICAR + GW1516
Clen + Keto + Yohimbine
Tamox / Clom / Anast
MISCELLANEOUS
Custom Order: CO_061013NH
Expedited Service
Foreign Reship Fee
Legal Disclaimer for Download
Priority Shipping
Shipping Insurance $100-$299
Shipping Insurance $1000-$3000
Shipping Insurance $25-$99
Shipping Insurance $300-$599
Shipping Insurance $600-$999
Special Handling Fee $16
Special Handling Fee $30
test

Selegiline 300mg, 30ml

 [SN30]
 $44.00 
Selegiline 300mg, 30ml

Selegiline

 

Selegiline, better known by the trade-name Deprenyl, was discovered by a Hungarian scientist named Dr. Joseph Knoll in the 1960s.  Dr. Knoll initially developed Selegiline as a potential antidepressant, but the drug has since been approved for treatment for Parkinson's disease in many countries.[1]

 

A Canadian named Dr. Morton Shulman, who took the drug for Parkinson's disease in the late 1980s, reported that "deprenyl halted the course of his disease."[1]  After investigating the drug further, Dr. Shulman began to seek approval for the drug as a prophylactic life-extender for use in pets.[1,7]

 

Studies in rats and other animals have shown that a fairly lose dose of Selegiline can extend life greatly, as much as 30% or more.[5,7,8,9]  This is likely through at least two mechanisms: Selegiline inhibits production of MAO-B, a chemical responsible for breakdown of dopamine; as people and rats age, MAO-B breaks down dopamine more effectively (starting in the fourth decade of human life) and continues to increase progressively in effectiveness by about 13% each year.[3]  These effects are strikingly similar to the effects of Parkinson's disease, and studies have revealed that in elderly human brains the dopamine levels are often as low as a late-stage Parkinson's patient.[3]  Another possible mechanism responsible for the longevity effect demonstrated with Selegiline trials is that it "greatly increases" the antioxidant SOD or superoxide dismutase, one of the body's three major antioxidant systems.[1,4,5,8,9]  Inferences drawn from this should be framed against the strong possibility that increasing SOD without increasing glutathione peroxidase and catalase could be disruptive or harmful to the balance of bodily systems.[1]

 

Despite less-than-optimal results treating depression when taken orally, Selegiline has been proven to be "an effective and well-tolerated mono-amine oxidase inhibitor for the treatment of depression" when applied in a transdermal patch in doses as low as 6mg every 24 hours. [2]

 

Regarding application as an antidepressant, Culpepper and Kovalick conclude that:

The Selegiline transdermal system provides several advantages compared to orally administered MAOIs, including minimal interaction with dietary tyramine and prolonged exposure to the parent compound, while offering a favorable side effect profile. As a result, treatment at the lowest effective dose of 6 mg/24 hours can be administered without the need for dietary modifications.[2]

 

The history of Selegiline and its various uses provide insight into the drug approval process and even highlights medical biases in treatment options that are somewhat outside the scope of a research article, but nonetheless bear mentioning.  For further reading see resources [1,6].  Despite demonstrated effectiveness in Parkinson's treatment, Cotton observes that the drug is underutilized as a treatment, particularly in the critical beginning-stages of the disease in patients where early detection is achieved.[11]  Dr. Knoll  remains the greatest advocate of the drug for various use, which generates suspicion in the medical community where impartiality and objectivity are valued.[1,11]  Dr. Knoll's novel recommendation that Selegiline be prescribed as a prophylactic or preventative treatment for all middle-aged adults for Parkinson's and age-related decline has drawn mixed reactions, and is noteworthy for being the first medical recommendation of that type to come to light in the mainstream scientific community.[1,11]  From a policy perspective, since Selegiline is far from side-effect free (like most effective treatment options of any nature), the recommendation is controversial because any prophylactic drug administered to a largely healthy population must be weighed against the medical oath of "Primum non nocere" (First, do no harm).

 

Cititations:

[1]Emanuelson, Jerry.  "Deprenyl." (http://www.futurescience.com/deprenyl.html)

[2]Culpepper L, Kovalick LJ.  A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression.  Prim Care Companion J Clin Psychiatry. 2008;10(1):25-30.

[3]Knoll, J. "Deprenyl Medication: A Strategy To Modulate the Age-Related Decline of the Striatal Dopaminergic System" Journal of the American Geriatric Society. V.40., No.8, August, 1992, pp. 839-847.

[4]Kushleika, J. and others. "Selegiline and Lymphocyte Superoxide Dismutase Activities in Parkinson's Disease." V. 39, No.3, March, 1996. pp.378-381.

[5]Carrillo, M.C. and others. "Long Term Treatment with (-)Deprenyl Reduces the Optimal Dose as well as the Effective Dose Range for Increasing Antioxidant Enzyme Activities in Old Mouse Brain." Life Science. 1996: Vol.59, No.13. pp.1047-1057.

[6]Best, Ben.  "Can Deprenyl (Selegiline) Extend Human Lifespan?"http://www.benbest.com/lifeext/deprenyl.html

[7]W.W. Ruehl, et.al.  "Treatment with L-Deprenyl Prolongs Life in Elderly Dogs." Life Sciences, 61:1037-1044 (1997).

[8]M-C. Carrillo, et.al.  "(-)Deprenyl Increases Activities of

SuperOxide Dismutase and Catalase in certain Brain Regions in Old Male Mice."   Life Sciences, 54:975-981 (1994).

[9]M-C. Carrillo, et.al. "(-)Deprenyl Increases Activities of SuperOxide Dismutase (SOD) in Striatum of Dog Brain."  Life Sciences, 54:1483-1489 (1994).

[10]Cotton, Paul. "Many Researchers, Few Clinicians, Using Drug That May Slow, Even Prevent, Parkinson's" Journal of the American Medical Association. Vol. 264, No. 9. Sept. 5, 1990. pp.1083-1084.

[11]Sonsalla, P.K. and Golbe L.I. "Deprenyl as Prophylaxis Against Parkinson's Disease?" Clinical Neuropharmacology. Vol. 11, No. 6., pp. 500-511.

 

*The latter article is intended for educational / informational purposes only. THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

This product was added to our catalog on Friday 06 March, 2009.
Reviews Add to Wish List
Quantity:     
Customers who bought this product also purchased
 
 
Shopping Cart
  Now in your cart 0 items
 
Your Account
 
Your Email Address
Your Password
 
Information
   
BestSellers
   
Featured
 
  SARMs S4 25mg / ml, 60ml
 
 

SARMs S4 25mg / ml, 60ml

$139.00
Comments

Write a review on this product!
Who's Online
  There currently are 23 guests online.